2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow Leukemia, Chronic Lymphatic: new trials by email Literature Review of Leukemia, Chronic Lymphatic trials Research Report on Leukemia, Chronic Lymphatic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Ibrutinib, Fludarabine, Pembrolizumab - B-Cell Chronic Lymphocytic Leukemia, B-Lymphocytic Leukemia, Chronic | Phase 2 | Completed | National Heart, Lung, and Blood Institute (NHLBI) | 15 | 2017-09-22 | 2026-01-30 |
| iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL Peptide Vaccine, Imiquimod - Leukemia, Chronic Lymphatic | Phase 2 | Completed | University Hospital Tuebingen | 56 | 2016-10-05 | 2022-11-28 |
Leukemia, Lymphocytic, Chronic, B-Cell (2) · Chromosome 17 deletion (1)
Chronic Disease (2) · Disease Attributes (2) · Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, B-Cell (2) · Leukemia, Lymphoid (2) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2)
Imiquimod (1) · Protein Subunit Vaccines (1) · fludarabine (1) · fludarabine phosphate (1) · ibrutinib (1) · pembrolizumab (1)
National Heart, Lung, and Blood Institute (NHLBI) (1) · University Hospital Tuebingen (1)
Germany (1) · United States (1)